Ernexa Presents Preclinical Data on Lead Cell Therapy Candidate ERNA-101 at ASH Annual Meeting.

Ernexa Therapeutics presented new preclinical data on its lead cell therapy candidate, ERNA-101, at the American Society of Hematology Annual Meeting. The data showed that ERNA-101 can rapidly and durably reprogram immunosuppressive tumor microenvironments into immune-active states to combat cancer. The proprietary platform engineers iPSCs into iMSCs, potentially overcoming resistance in solid tumors and hematologic malignancies, and offers a scalable, off-the-shelf approach to local cytokine delivery.